Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.forsciint.2008.10.023 Byline: Paula Triunfante (a), Maria Elisa Soares (a), Agostinho Santos (b), Susana Tavares (c), Helena Carmo (a), Maria de Lourdes Bastos (a) Keywords: Mercury intoxication; Forensic analysis; Mercury speciation Abstract: We report two cases of fatal intoxications with mercury, one intentional and the other allegedly resulting from a drug formulation mistake. Both cases occurred in the year of 2004. The first case refers to a man who ingested a great portion of a mercuric chloride solution. He attended a hospital emergency, submitted to treatment, but died after 49 days. In the second case, a woman applied on the chest skin an ointment containing a great quantity of mercury bromide. After 7 days of treatment in the hospital, she died. In both cases, samples of tissues and organs were collected at autopsy for mercury analysis. Because methylation of mercury in humans after exposure to metallic or inorganic mercury is almost unknown, both total mercury and methylmercury were quantified in the post-mortem samples. The quantifications were carried out by Cold Vapour Generation Atomic Absorption Spectrometry for total mercury and by HPLC-UV for methylmercury. The total mercury contents found in the post-mortem fluid and tissue samples were consentaneous with mercury poisoning. For the first case, the concentrations found, expressed in [mu]g/g wet weight, were in the liver 49.9, lung 3.27 and brain 0.33, and for blood 11.7[mu]g/mL. For the second case, the concentrations expressed in [mu]g/g wet weight were in the liver 46.6, lung 14.6, brain 0.21, kidney 77.7, stomach 7.12, spleen 6.4 and heart 2.34, and for blood and urine 2.95 and 1.40[mu]g/mL, respectively. Only in the first case was methylmercury found and quantified in liver (1.70[mu]g/g wet weight) and in blood (0.15[mu]g/mL) samples. Author Affiliation: (a) REQUIMTE, Toxicology Department, Faculty of Pharmacy, University of Porto, Rua Anibal Cunha 164, 4099-030 Porto, Portugal (b) National Institute of Legal Medicine, North Delegation, Jardim Carrilho Videira, 4050-167 Porto, Portugal (c) National Institute of Legal Medicine, Centre Delegation, Largo da Se Nova, 3000-213 Coimbra, Portugal Article History: Received 21 April 2008; Revised 25 September 2008; Accepted 25 October 2008

Gold nanoparticles (AuNPs) have biomedical application on imaging and due to increased optical performance, star-shaped AuNPs are of special interest. Because shape, size and capping greatly influence their toxicokinetics and toxicodynamics, a systematic multiparametric comparative study of the influence of these parameters on the cytotoxicity, internalization, and in vitro permeability was conducted in human Cerebral Microvascular Endothelial Cell line (hCMEC/D3), an in vitro model of the human blood-brain barrier (BBB). AuNPs of different size (14 nm and ∼50 nm), shape (spheres and stars), and coating (11-mercaptoundecanoic acid or MUA and sodium citrate) were synthesized and fully characterized. The time- and concentration-dependent cytotoxic profile of the tested AuNPs differed for the different AuNPs. Generally, toxicity was greater for stars relative to sphere-shaped AuNPs, and citrate coating was more toxic than MUA. Regarding the influence of size, smaller-sized AuNPs were more cytotoxic when compared at the same Au concentration. However, when the concentration of AuNPs was expressed as the number of AuNPs/mL, a higher degree of cytotoxicity was noted for the larger ̴50 nm AuNPs. To understand the influence of size, shape and capping, a systematic study design, in which only one of the variables changes, is determinant for correct data interpretation. Considering the results herein presented, for the sake of comparison of differently-sized AuNPs, it is preferable to design the study based upon the number of nanoparticles, since at a fixed Au concentration the number of particles available to promote effect is higher for smaller-sized AuNPs. Cellular internalization also differed among the tested AuNPs; although all were unable to cross the in vitro BBB, the intracellularly accumulated AuNPs can induce cell damage and later compromise BBB integrity and permeability. [ABSTRACT FROM AUTHOR]

Gold nanoparticles (AuNPs) are promising nanoplatforms for drug therapy, diagnostic and imaging. However, biological comparison studies for different types of AuNPs fail in consistency due to the lack of sensitive methods to detect subtle differences in the expression of toxicity. Therefore, innovative and sensitive approaches such as metabolomics are much needed to discriminate toxicity, specially at low doses. The current work aims to compare the in vivo toxicological effects of gold nanospheres versus gold nanostars (of similar ~40 nm diameter and coated with 11-mercaptoundecanoic acid) 24 h after an intravenous administration of a single dose (1.33 × 1011 AuNPs/kg) to Wistar rats. The biodistribution of both types of AuNPs was determined by graphite furnace atomic absorption spectroscopy. The metabolic effects of the AuNPs on their main target organ, the liver, were analyzed using a GC-MS-based metabolomic approach. Conventional toxicological endpoints, including the levels of ATP and reduced and oxidized glutathione, were also investigated. The results show that AuNPs preferentially accumulate in the liver and, to a lesser extent, in the spleen and lungs. In other organs (kidney, heart, brain), Au content was below the limit of quantification. Reduced glutathione levels increased for both nanospheres and nanostars in the liver, but ATP levels were unaltered. Multivariate analysis showed a good discrimination between the two types of AuNPs (sphere- versus star-shaped nanoparticles) and compared to control group. The metabolic pathways involved in the discrimination were associated with the metabolism of fatty acids, pyrimidine and purine, arachidonic acid, biotin, glycine and synthesis of amino acids. In conclusion, the biodistribution, toxicological, and metabolic profiles of gold nanospheres and gold nanostars were described. Metabolomics proved to be a very useful tool for the comparative study of different types of AuNPs and raised awareness about the pathways associated to their distinct biological effects. [ABSTRACT FROM AUTHOR]

Gold nanoparticles (AuNPs) are highly attractive to biomedical applications. Here, we investigated the effects of (i) ca. 15 nm spherical AuNPs capped with citrate or 11-mercaptoundecanoic acid (MUA) and (ii) ca. 60 nm spherical citrate-capped AuNPs, and ca. 60 nm MUA-capped star-shaped AuNPs on the cytotoxicity, cellular uptake and permeability, using media supplemented or not with 1% fetal bovine serum (FBS) on caucasian colon adenocarcinoma Caco-2 cells. In addition, the colloidal stability of the nanoparticles in media (supplemented or not) was assessed after 24 h-incubations at 60 μM. The 60 nm gold nanospheres and stars were administrated orally to Wistar rats in order to evaluate their systemic absorption and biodistribution after 24 h. At non-supplemented media settings, citrate-capped gold nanoparticles seem to be more toxic than their MUA-capped counterparts. Also, smaller nanoparticles show higher toxicity than larger ones. The use of cell culture media with 1% FBS not only increased the stability of all AuNPs, as also significantly reduced their cytotoxicity. In the uptake studies, higher AuNPs incorporation was noticed in serum supplemented media, this effect being particularly significant for the 60 nm nanoparticles. Cellular incorporation depended also on the capping agent and size. None of the tested samples crossed the in vitro intestinal barrier. Confirming the in vitro results, the in vivo biodistribution study of the 60 nm AuNPs orally given to rats showed that their systemic absorption is low and that they are mainly eliminated through the faeces. Altogether, these preliminary results suggest that our novel AuNPs have high potential to be considered promising candidates for application in diagnostics or drug delivery at the intestinal level, showing high biocompatibility. However, unless it is desired that these nanomaterials avoid systemic absorption upon oral administration, additional functionalization should be sought to increase their low bioavailability.